Recent advancements in liquid biopsy technology have opened new frontiers in the detection and differentiation of biomarkers crucial for disease diagnosis and monitoring. Researchers at the RIKEN Molecular Physiology Laboratory have developed a novel liquid biopsy method that utilizes nanoparticle-enhanced Raman spectroscopy to identify closely related enzymes, significantly improving the accuracy and reliability of biomarker profiling.

Overview of Liquid Biopsy Technology

Liquid biopsies have transformed the landscape of medical diagnostics, offering a non-invasive method to detect biomarkers in body fluids such as blood, saliva, and urine. They are particularly valuable for identifying enzymes associated with various diseases, including cancers and neurological disorders. The increased interest in liquid biopsies was particularly evident during the COVID-19 pandemic, highlighting their potential for rapid diagnostic testing.

Current Methods and Their Limitations

Traditionally, liquid biopsies rely on fluorescence-based detection methods, which measure the fluorescence emitted when a target enzyme interacts with a reporter substrate. This approach enables sensitive detection of enzymes even at low concentrations. However, the broad wavelength range of fluorescence emission limits the ability to distinguish between enzymes that are structurally similar. Hence, there is a critical need for improved detection methods that overcome these limitations.

Raman Spectroscopy as a Solution

Raman spectroscopy offers a complementary approach that generates narrow, well-defined spectral peaks providing specific molecular fingerprints. According to Rikiya Watanabe, a researcher at RIKEN, "Raman spectroscopy has a key advantage of having an exceptionally high discriminative ability." However, one of the major challenges in using Raman spectroscopy is the inherent weakness of its signals, which complicates the rapid detection of enzymes at low concentrations.

Enhancing Raman Signals with Nanoparticles

The innovative method developed by Watanabe and colleagues incorporates metallic nanoparticles, specifically silver nanoparticles, which enhance the Raman signal by approximately one million times. This enhancement allows for better control and reproducibility of the Raman signals, making them suitable for reliable liquid biopsy applications.

"We developed a microchip that significantly improved the reproducibility and quantitative reliability of enhanced Raman signals," remarks Watanabe.

Application: Distinguishing Biomarkers

One significant application of this new method is the differentiation between two closely related enzymes: acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The ability to distinguish these enzymes is crucial, particularly in the context of neurodegenerative diseases.

Enzyme Function Significance in Dementia
Acetylcholinesterase (AChE) Hydrolyzes acetylcholine in synapses Higher levels found in Alzheimer's patients
Butyrylcholinesterase (BChE) Hydrolyzes butyrylcholine and acetylcholine May modulate AChE activity; less specific

Watanabe's team discovered that AChE is typically present in greater quantities among patients diagnosed with Alzheimer's compared to those suffering from vascular cognitive disorders. This finding presents the potential for using AChE levels as a biomarker to stratify subtypes of dementia, suggesting a new avenue for diagnosis and treatment strategies.

Conclusion and Future Directions

The novel liquid biopsy method developed by RIKEN researchers presents not only a significant leap forward in biomarker detection but also highlights the broader implications of using advanced spectroscopy techniques in medical diagnostics. Future research will likely focus on optimizing this method further and exploring its applicability to various other biomarkers associated with different diseases.

For more details, refer to the publication by Jun Ando et al. titled "Digital SERS bioanalysis of single-enzyme biomarkers" in the Proceedings of the National Academy of Sciences (2025).

References

  • Ando, J., et al. (2025). Digital SERS bioanalysis of single-enzyme biomarkers. Proceedings of the National Academy of Sciences.
  • Watanabe, R. (2026). Liquid biopsy method uses nanoparticle Raman signals to separate two lookalike enzymes. Retrieved from Phys.org.